Tim Shaw

机构：AbbVie (United Kingdom)

发表论文 24 篇 · 总被引 3385 次 · h-index 11

代表论文

• Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis (2004 · New England Journal of Medicine · 被引 2630)
• Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis (2023 · RMD Open · 被引 214)
• Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B‐Cell Levels Do Not Correlate With Clinical Response (2007 · The Journal of Clinical Pharmacology · 被引 149)
• Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE (2011 · Annals of the Rheumatic Diseases · 被引 108)
• Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate (2010 · Annals of the Rheumatic Diseases · 被引 100)
• Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis (2015 · Expert Opinion on Pharmacotherapy · 被引 47)